PATENT CLAIM ANALYSIS

Application Number: 15743560
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "04400A"]

Abstract:
The invention provides methods of treating polyglutamine diseases, e.g., spinocerebellar ataxia Type 6, in a subject, comprising administering to the subject an IRES inhibitor in an amount effective for treating the SCA6 in the subject. Also provided herein are the IRES inhibitors, and pharmaceutical compositions comprising the same.

Claim (Index 8):
A method of treating a subject with a predisposition to spinocerebellar ataxia Type 6 (SCA6), comprising the step of administering to the subject (i) an antisense molecule, (ii) a vector encoding the antisense molecule, (iii) a cell comprising the vector or antisense molecule, (iv) a extracellular vesicle comprising the antisense molecule, or (v) a combination thereof, wherein the antisense molecule binds to a portion of an IRES of a CACNA1A gene comprising the sequence of SEQ ID NO: 180, optionally, wherein the antisense molecule binds to Argonaute 4 (Ago4), optionally, wherein the vector is a recombinant expression vector of any one of  claims 18  to  28 , wherein the cell is a cell of  claim 30 , or the extracellular vesicle is an extracellular vesicle of  claim 29 .

Metadata:
- Claim Count in Document: 1.0
- Percentile: 86.0
- Lexical Diversity: 1.44737
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15024492', '15573417', '14011539', '12963793', '15508857']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6868572272169605
- 35 USC 102 Novelty (BERT): 0.5800653244326924
- Combined Prediction Score: 0.6761780369385337
- Mean Citation Score: 302.607136
- Max Citation Score: 497.57776
- Similarity Product: 369.0660260395623

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test